Bree R Eaton1, Renjian Jiang2, Mylin A Torres3, Shannon T Kahn3, Karen Godette3, Timothy L Lash2, Kevin C Ward2,4. 1. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. brupper@emory.edu. 2. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. 3. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 4. Georgia Center for Cancer Statistics, Georgia SEER Registry, Atlanta, Georgia.
Abstract
BACKGROUND: The purpose of the current study was to evaluate the impact of radiotherapy (RT) among women aged ≥ 70 years with T1-2N0 estrogen receptor (ER)-negative breast cancer using Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked data. METHODS: The study included 3432 women, 2850 of whom received and 582 of whom did not receive RT after breast-conserving surgery. Outcomes were estimated by the cumulative incidence method and compared with the Gray test. The Fine and Gray subdistribution hazard regression models were used to assess the impact of RT and other variables. RESULTS: Women who received RT were more commonly aged <75 years (42% vs 16%), had T1 tumors (78% vs 65%), ductal carcinoma histology (91% vs 88%), a Charlson-Deyo Comorbidity Index of 0 (41% vs 25%), and had received chemotherapy (29% vs 12%). The 5-year cumulative incidence of mastectomy and breast cancer-specific death for patients who received versus those did not receive adjuvant RT was 4.9% and 8.3% versus 10.8% and 24.1%, respectively (P<.001). On multivariable analysis, the omission of RT was found to be an independent predictor of an increased risk of mastectomy (hazard ratio, 2.33; 95% confidence interval, 1.56-3.49). Among women aged ≥ 80 years or with T1N0 tumors, the mastectomy incidence with or without receipt of RT was 3.4% vs. 6.9%, and 5.3% vs 7.7%, respectively. CONCLUSIONS: The use of adjuvant RT after breast-conserving surgery in older women with T1-2N0 estrogen receptor-negative breast cancer is associated with a reduced incidence of future mastectomy and breast cancer death. The magnitude of benefit may be small for women aged ≥80 years or those with T1 tumors. Cancer 2016;122:3059-3068.
BACKGROUND: The purpose of the current study was to evaluate the impact of radiotherapy (RT) among women aged ≥ 70 years with T1-2N0 estrogen receptor (ER)-negative breast cancer using Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked data. METHODS: The study included 3432 women, 2850 of whom received and 582 of whom did not receive RT after breast-conserving surgery. Outcomes were estimated by the cumulative incidence method and compared with the Gray test. The Fine and Gray subdistribution hazard regression models were used to assess the impact of RT and other variables. RESULTS:Women who received RT were more commonly aged <75 years (42% vs 16%), had T1 tumors (78% vs 65%), ductal carcinoma histology (91% vs 88%), a Charlson-Deyo Comorbidity Index of 0 (41% vs 25%), and had received chemotherapy (29% vs 12%). The 5-year cumulative incidence of mastectomy and breast cancer-specific death for patients who received versus those did not receive adjuvant RT was 4.9% and 8.3% versus 10.8% and 24.1%, respectively (P<.001). On multivariable analysis, the omission of RT was found to be an independent predictor of an increased risk of mastectomy (hazard ratio, 2.33; 95% confidence interval, 1.56-3.49). Among women aged ≥ 80 years or with T1N0 tumors, the mastectomy incidence with or without receipt of RT was 3.4% vs. 6.9%, and 5.3% vs 7.7%, respectively. CONCLUSIONS: The use of adjuvant RT after breast-conserving surgery in older women with T1-2N0 estrogen receptor-negative breast cancer is associated with a reduced incidence of future mastectomy and breast cancer death. The magnitude of benefit may be small for women aged ≥80 years or those with T1 tumors. Cancer 2016;122:3059-3068.
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Ian H Kunkler; Linda J Williams; Wilma J L Jack; David A Cameron; J Michael Dixon Journal: Lancet Oncol Date: 2015-01-28 Impact factor: 41.316
Authors: Jeffrey M Albert; Diane D Liu; Yu Shen; I-Wen Pan; Ya-Chen Tina Shih; Karen E Hoffman; Thomas A Buchholz; Sharon H Giordano; Benjamin D Smith Journal: J Clin Oncol Date: 2012-06-25 Impact factor: 44.544
Authors: Jona A Hattangadi-Gluth; Jennifer Y Wo; Paul L Nguyen; Rita F Abi Raad; Meera Sreedhara; Andrzej Niemierko; Phoebe E Freer; Dianne Georgian-Smith; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-19 Impact factor: 7.038
Authors: G Cancello; P Maisonneuve; N Rotmensz; G Viale; M G Mastropasqua; G Pruneri; E Montagna; S Dellapasqua; M Iorfida; A Cardillo; P Veronesi; A Luini; M Intra; O Gentilini; E Scarano; A Goldhirsch; M Colleoni Journal: Breast Cancer Res Treat Date: 2011-03-31 Impact factor: 4.872
Authors: Benjamin D Smith; Cary P Gross; Grace L Smith; Deron H Galusha; Justin E Bekelman; Bruce G Haffty Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl McCormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman B Muss; Eric Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Michela Dispinzieri; Eliana La Rocca; Elisabetta Meneghini; Alba Fiorentino; Laura Lozza; Serena Di Cosimo; Massimiliano Gennaro; Vito Cosentino; Milena Sant; Emanuele Pignoli; Riccardo Valdagni; Francesca Bonfantini; Maria Carmen De Santis Journal: Med Oncol Date: 2018-06-16 Impact factor: 3.064
Authors: Montserrat Pazos; Stephan Schönecker; Daniel Reitz; Paul Rogowski; Maximilian Niyazi; Filippo Alongi; Christiane Matuschek; Michael Braun; Nadia Harbeck; Claus Belka; Stefanie Corradini Journal: Breast Care (Basel) Date: 2018-05-24 Impact factor: 2.860
Authors: E La Rocca; E Meneghini; L Lozza; A Fiorentino; A Vitullo; C Giandini; F Bonfantini; S Di Cosimo; M Gennaro; M Sant; E Pignoli; R Valdagni; Maria Carmen De Santis Journal: J Cancer Res Clin Oncol Date: 2020-05-13 Impact factor: 4.553
Authors: Nam P Nguyen; Ulf Karlsson; Eromosele Oboite; Julio Alvarenga; Juan Godinez; Alice Zamagni; Micaela Motta; Satya Bose; Vincent Vinh-Hung Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241